Speaker Profile
Ph.D., CEO, Lyora Tx
Biography
Pamela Stetkiewicz, Ph.D., is Chief Executive Officer of Lyora Therapeutics and a biotechnology executive with more than two decades of experience in drug discovery and development. Her career spans scientific research, program leadership, business development, organizational design, and the advancement of therapeutic programs from early research into clinical development. Before joining Lyora, she held senior leadership roles at Arbor Biotechnologies, Flagship Pioneering, Editas Medicine, and the Novartis Institutes for Biomedical Research. Across these organizations, she has worked at the interface of emerging biology, platform technologies, portfolio strategy, and development execution. At Lyora, she is leading a company focused on genetic medicines for inherited retinal and sensory disorders, including programs that use RNA and gene-editing approaches to address disease-causing mutations. Dr. Stetkiewicz is known for building multidisciplinary teams and scalable development frameworks that connect scientific innovation with the operational and strategic requirements needed to move new medicines toward patients.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Catriona Jamieson, UC San Diego
PMWC Award Ceremony
• Emmanuelle Charpentier, Max Planck (J. Craig Venter Visionary Award · Nobel Laureate)
• Jay Bradner, Amgen (Pioneer)
• Adrian Krainer, Cold Spring Harbor Laboratory (Luminary)
• Randy Schekman, UC Berkeley (Nobel Laureate, Pioneer)
Featured Speakers
• Emmanuelle Charpentier, Max Planck
• Randy Schekman, UC Berkeley
• Jay Bradner, Amgen
• Adrian Krainer, Cold Spring Harbor Laboratory
• Alexis C. Komor, UC San Diego
• Nicole Gaudelli, GV
• Rachel Haurwitz, Caribou Bio
• Gene Yeo, UC San Diego
• Timothy Yu, Boston Children's / Harvard
• Shicheng Guo, Arrowhead Pharmaceuticals
• Mark A. Kay, Stanford
• Niren Murthy, UC Berkeley
• Ben Deverman, Broad Institute
• Stanley Crooke, n-Lorem / Ionis
Programming Protein Fate
Molecular glues, degraders, and induced proximity crossing into medicines.
Genome Editing Beyond the First Wave
Base, prime, and CRISPR-enabled editing moving from correction to clinic.
RNA Editing, Splice Modulation & Programmable RNA
RNA editing, ASOs, and splice modulation with chemistry already reaching patients.
In Vivo Delivery & Vector Engineering
AAV, LNP, and next-generation vectors that decide what is treatable.
From N-of-1 to Platform
Evidence, CMC, regulation, and access for individualized genetic medicines.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
